AR020147A1 - DERIVATIVES OF CARBOXYLIC ACIDS, ITS USE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF COMPOUNDS DERIVED FROM CARBOXYLIC ACIDS ASINTERMEDIARIES FOR THEIR PREPARATION, USE OF A STRUCTURE FRAGMENT DERIVED FROM CARBOXYLIC ACIDS IN THE MUSIC COMPOSITION COMPOSITIONS - Google Patents
DERIVATIVES OF CARBOXYLIC ACIDS, ITS USE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF COMPOUNDS DERIVED FROM CARBOXYLIC ACIDS ASINTERMEDIARIES FOR THEIR PREPARATION, USE OF A STRUCTURE FRAGMENT DERIVED FROM CARBOXYLIC ACIDS IN THE MUSIC COMPOSITION COMPOSITIONSInfo
- Publication number
- AR020147A1 AR020147A1 ARP990103985A ARP990103985A AR020147A1 AR 020147 A1 AR020147 A1 AR 020147A1 AR P990103985 A ARP990103985 A AR P990103985A AR P990103985 A ARP990103985 A AR P990103985A AR 020147 A1 AR020147 A1 AR 020147A1
- Authority
- AR
- Argentina
- Prior art keywords
- carboxylic acids
- endothelin
- asintermediaries
- derivatives
- derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La endotelina es un péptido formado por 21 aminoácidos, que es sintetizada y liberada por el endotelio vascular. La endotelina existe en tresisoformas, ET-1, ET-2 y ET-3. A continuacion endotelina o ET designan a una o a todas las isoformas deendote lina. La endotelina es unpotente vasoconstrictor y tiene un fuerte efecto sobre el tono vascular. Se sabe que esa vasoconstriccion es provocada por la ligadura de endotelina a sureceptor. La liberacion aumentada o anormal de endotelinaprovoca una co ntraccion vascular continua en los vasos sanguíneos periféricos, renales ycerebrales, lo que puede llevar a enfermedades. Como se ha informado en la bibliografía, la endotelina está involucrada en una serie de enfermedades.Estascomprenden: hipertoni a, infarto de miocardio agudo, hipertonía pulmonar, síndrome de Raynaud, vasoespasmos cerebrales, aplopejía, hipertrofia prostáticabenigna, ateroesclerosis y asma.Endothelin is a peptide formed by 21 amino acids, which is synthesized and released by the vascular endothelium. Endothelin exists in tresisoforms, ET-1, ET-2 and ET-3. Then endothelin or ET designate one or all of the isoforms of the line. Endothelin is a potent vasoconstrictor and has a strong effect on vascular tone. It is known that vasoconstriction is caused by the ligation of endothelin to its receptor. The increased or abnormal release of endothelin causes continuous vascular compression in the peripheral, renal and cerebrospinal blood vessels, which can lead to diseases. As reported in the literature, endothelin is involved in a number of diseases. These include: hypertoni, acute myocardial infarction, pulmonary hypertonia, Raynaud's syndrome, cerebral vasospasms, aplopegia, benign prostatic hypertrophy, atherosclerosis and asthma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19836044A DE19836044A1 (en) | 1998-08-10 | 1998-08-10 | New 2-(hetero)aryl-alkanoic acid derivatives, useful as mixed endothelin receptor antagonists, e.g. for treating cardiac insufficiency, restenosis, hypertension or prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020147A1 true AR020147A1 (en) | 2002-04-10 |
Family
ID=7876981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990103985A AR020147A1 (en) | 1998-08-10 | 1999-08-10 | DERIVATIVES OF CARBOXYLIC ACIDS, ITS USE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF COMPOUNDS DERIVED FROM CARBOXYLIC ACIDS ASINTERMEDIARIES FOR THEIR PREPARATION, USE OF A STRUCTURE FRAGMENT DERIVED FROM CARBOXYLIC ACIDS IN THE MUSIC COMPOSITION COMPOSITIONS |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1104410A1 (en) |
| JP (1) | JP2002522531A (en) |
| KR (1) | KR20010072378A (en) |
| CN (1) | CN1323298A (en) |
| AR (1) | AR020147A1 (en) |
| AU (1) | AU5374199A (en) |
| BG (1) | BG105236A (en) |
| BR (1) | BR9912889A (en) |
| CA (1) | CA2340167A1 (en) |
| CO (1) | CO5261504A1 (en) |
| DE (1) | DE19836044A1 (en) |
| HK (1) | HK1042086A1 (en) |
| HR (1) | HRP20010164A2 (en) |
| HU (1) | HUP0104007A3 (en) |
| ID (1) | ID27965A (en) |
| IL (1) | IL140915A0 (en) |
| NO (1) | NO20010622D0 (en) |
| PL (1) | PL345998A1 (en) |
| SK (1) | SK832001A3 (en) |
| TR (1) | TR200100427T2 (en) |
| WO (1) | WO2000009489A1 (en) |
| ZA (1) | ZA200101975B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19924892A1 (en) * | 1999-06-01 | 2000-12-07 | Basf Ag | New carboxylic acid derivatives with aryl-substituted nitrogen heterocycles, their production and use as endothelin receptor antagonists |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19636046A1 (en) * | 1996-09-05 | 1998-03-12 | Basf Ag | New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists |
-
1998
- 1998-08-10 DE DE19836044A patent/DE19836044A1/en not_active Withdrawn
-
1999
- 1999-08-07 WO PCT/EP1999/005728 patent/WO2000009489A1/en not_active Application Discontinuation
- 1999-08-07 CN CN99811981A patent/CN1323298A/en active Pending
- 1999-08-07 ID IDW20010326A patent/ID27965A/en unknown
- 1999-08-07 EP EP99939457A patent/EP1104410A1/en not_active Withdrawn
- 1999-08-07 SK SK83-2001A patent/SK832001A3/en unknown
- 1999-08-07 PL PL99345998A patent/PL345998A1/en not_active Application Discontinuation
- 1999-08-07 BR BR9912889-6A patent/BR9912889A/en not_active Application Discontinuation
- 1999-08-07 CA CA002340167A patent/CA2340167A1/en not_active Abandoned
- 1999-08-07 AU AU53741/99A patent/AU5374199A/en not_active Abandoned
- 1999-08-07 IL IL14091599A patent/IL140915A0/en unknown
- 1999-08-07 HU HU0104007A patent/HUP0104007A3/en unknown
- 1999-08-07 KR KR1020017001731A patent/KR20010072378A/en not_active Application Discontinuation
- 1999-08-07 JP JP2000564942A patent/JP2002522531A/en active Pending
- 1999-08-07 TR TR2001/00427T patent/TR200100427T2/en unknown
- 1999-08-10 AR ARP990103985A patent/AR020147A1/en not_active Application Discontinuation
- 1999-08-10 CO CO99050715A patent/CO5261504A1/en not_active Application Discontinuation
-
2001
- 2001-02-06 NO NO20010622A patent/NO20010622D0/en not_active Application Discontinuation
- 2001-02-09 BG BG105236A patent/BG105236A/en unknown
- 2001-03-08 HR HR20010164A patent/HRP20010164A2/en not_active Application Discontinuation
- 2001-03-09 ZA ZA200101975A patent/ZA200101975B/en unknown
-
2002
- 2002-05-15 HK HK02103679.0A patent/HK1042086A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20010164A2 (en) | 2002-04-30 |
| HK1042086A1 (en) | 2002-08-02 |
| DE19836044A1 (en) | 2000-02-17 |
| JP2002522531A (en) | 2002-07-23 |
| HUP0104007A3 (en) | 2002-12-28 |
| WO2000009489A1 (en) | 2000-02-24 |
| IL140915A0 (en) | 2002-02-10 |
| PL345998A1 (en) | 2002-01-14 |
| EP1104410A1 (en) | 2001-06-06 |
| KR20010072378A (en) | 2001-07-31 |
| CA2340167A1 (en) | 2000-02-24 |
| ZA200101975B (en) | 2002-03-11 |
| ID27965A (en) | 2001-05-03 |
| CO5261504A1 (en) | 2003-03-31 |
| BR9912889A (en) | 2001-05-08 |
| CN1323298A (en) | 2001-11-21 |
| HUP0104007A2 (en) | 2002-05-29 |
| TR200100427T2 (en) | 2001-07-23 |
| NO20010622L (en) | 2001-02-06 |
| BG105236A (en) | 2001-12-29 |
| AU5374199A (en) | 2000-03-06 |
| NO20010622D0 (en) | 2001-02-06 |
| SK832001A3 (en) | 2001-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1124842T3 (en) | Betulinic acid derivatives useful for the treatment of neuroectodermal tumors | |
| BR0013653A (en) | Bicyclic androgen and progesterone receptor modulating compounds and production and use processes | |
| NO324217B1 (en) | Condensed azepine derivatives and their use as antidiuretic agents | |
| BE2015C026I2 (en) | 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens | |
| BG66084B1 (en) | Cyclopentanoindoles, compositions containing such compounds and their use | |
| DE60108236D1 (en) | 1,2,3,4-tetrahydroisoquinoline DERIVATIVES | |
| ECSP034603A (en) | SYNERGIC COMBINATIONS THAT INCLUDE A RHENINE INHIBITOR FOR CARDIOVASCULAR DISEASES | |
| AR028650A1 (en) | NEW COMPOSITIONS OF SUCCINICAL ALQUENIL ANHYDRIDE AND ITS USE | |
| DK0889877T3 (en) | Meta-substituted phenylene derivatives and their use as alpha-beta3 integrin antagonists or inhibitors | |
| MY129150A (en) | Novel sulfamides | |
| PE20020884A1 (en) | 4-FLUORO-N-INDAN-2-IL-BENZAMIDE AND ITS USE AS A PHARMACEUTICAL PRODUCT | |
| BRPI0110024B8 (en) | antitumour ecteinascidin derivatives, pharmaceutical composition comprising them and their use | |
| TR200401793T4 (en) | Perindopril salt and pharmaceutical compositions containing it. | |
| DK1254134T3 (en) | Derivatives of 1,3-dihydro-2H-indol-2-one and their use as ligands for the arginine vasopressin receptors V1B or V1B and V1A | |
| ATE250931T1 (en) | USE OF 5-HT4 ANTAGONISTS TO OVERCOME GASTROINTESTINAL DAMAGE CAUSED BY SEROTONIN REUPtake INHIBITORS | |
| CL2004000026A1 (en) | USE OF A COMPOSITION THAT INCLUDES 0 TO AROUND 29% OF CIS-CLOMIFEN AND AROUND 100 TO AROUND 71% OF TRANS-CLOMIFENE TO PREPARE A USEFUL DRUG TO INCREASE THE LEVELS OF TESTOSTERONE IN SERUM IN A MALE MALE. | |
| CA2378428A1 (en) | Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes | |
| CO4960655A1 (en) | NEW COMPOSITION AND ITS USE | |
| DK0811001T3 (en) | Benzothiazine dioxides as endothelin antagonists | |
| BR0113321A (en) | Pharmaceutical combination of angiotensin ii antagonists and angiotensin converting enzyme inhibitors i | |
| AR029371A1 (en) | UREA-PEPTOIDES OF INDOL AND INDAZOL AS ANTAGONISTS OF THE THROMBINE RECEPTOR, PHARMACEUTICAL COMPOSITION AND USE. | |
| AR020147A1 (en) | DERIVATIVES OF CARBOXYLIC ACIDS, ITS USE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF COMPOUNDS DERIVED FROM CARBOXYLIC ACIDS ASINTERMEDIARIES FOR THEIR PREPARATION, USE OF A STRUCTURE FRAGMENT DERIVED FROM CARBOXYLIC ACIDS IN THE MUSIC COMPOSITION COMPOSITIONS | |
| ATE342261T1 (en) | PYRAND DERIVATIVES AS INHIBITORS OF ACE AND NEP | |
| Coleman et al. | Non-Peptide αvβ3 antagonists. Part 3: Identification of potent RGD mimetics incorporating novel β-Amino acids as aspartic acid replacements | |
| AR020864A1 (en) | WET CLEANING TOWEL FOR HARD SURFACES. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |